首页> 外文期刊>Chromatographia >Fluorescence determination of sulphobutylether-beta-cyclodextrin sodium in human plasma and urine by size-exclusion chromatography with inclusion complex formation
【24h】

Fluorescence determination of sulphobutylether-beta-cyclodextrin sodium in human plasma and urine by size-exclusion chromatography with inclusion complex formation

机译:尺寸排阻色谱-包裹体配合物形成荧光法测定人血浆和尿中磺基丁基醚-β-环糊精钠

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

HPLC methods with fluorescence detection have been developed for the determination of sulphobutylether-beta -cyclodextrin sodium (SBECD), a novel excipient for use with drugs of limited aqueous solubility, in human plasma and urine. SBECD contains no chromophore or fluorophore but can be detected by size-exclusion HPLC using excitation and emission wavelengths of 290 and 360 nm when l-naphthol is included in the mobile phase. The guest-host inclusion complex SBECD forms with the l-naphthol restores the quenched fluorescence in the mainly aqueous environment of the mobile phase. Using simple solid phase extraction, recoveries of 41% were obtained using aminopropyl cartridges for urine and of 69% using end-capped cyclohexyl cartridges for plasma. These extracts were analysed using size exclusion HPLC. Both methods were precise, accurate and simple to perform. The working ranges were 4 to 200 mug mL(-1) and 50 to 1500 mug mL(-1) for plasma and urine respectively The lower limits of quantification were 4 mug mL(-1) for plasma and 50 mug mL(-1) for urine. The methods were also selective; no significant interferences were observed in six different sources of plasma or urine, or from a range of likely co-medicants. [References: 15]
机译:已开发出具有荧光检测功能的HPLC方法,用于测定磺基丁醚-β-环糊精钠(SBECD),这是一种在人血浆和尿液中与水溶性有限的药物一起使用的新型赋形剂。 SBECD不包含发色团或荧光团,但当流动相中包含1-萘酚时,可以使用290和360 nm的激发和发射波长,通过尺寸排阻HPLC进行检测。与1-萘酚形成的客体-主体包合物SBECD在流动相的主要水性环境中恢复了淬灭的荧光。使用简单的固相萃取,使用氨丙基药筒进行尿液回收率达到41%,使用封端环己基药柱进行血浆回收率达到69%。使用尺寸排阻HPLC分析这些提取物。两种方法都精确,准确且易于执行。血浆和尿液的工作范围分别为4到200毫升(-1)和50到1500毫升(-1)。定量的下限是血浆和尿液的定量下限为4毫升(-1)和50毫升(-1) )用于尿液。这些方法也是选择性的。在六种不同的血浆或尿液来源或一系列可能的辅助药物中,未观察到明显的干扰。 [参考:15]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号